Cryptococcal Meningitis Diagnostics and Screening in the Era of Point-of-Care Laboratory Testing.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
01 2019
Historique:
received: 31 07 2018
accepted: 07 09 2018
pubmed: 28 9 2018
medline: 31 1 2020
entrez: 28 9 2018
Statut: epublish

Résumé

Over the past ten years, standard diagnostics for cryptococcal meningitis in HIV-infected persons have evolved from culture to India ink to detection of cryptococcal antigen (CrAg), with the recent development and distribution of a point-of-care lateral flow assay. This assay is highly sensitive and specific in cerebrospinal fluid (CSF), but is also sensitive in the blood to detect CrAg prior to meningitis symptoms. CrAg screening of HIV-infected persons in the blood prior to development of fulminant meningitis and preemptive treatment for CrAg-positive persons are recommended by the World Health Organization and many national HIV guidelines. Thus, CrAg testing is occurring more widely, especially in resource-limited laboratory settings. CrAg titer predicts meningitis and death and could be used in the future to customize therapy according to burden of infection.

Identifiants

pubmed: 30257903
pii: JCM.01238-18
doi: 10.1128/JCM.01238-18
pmc: PMC6322457
pii:
doi:

Substances chimiques

Antigens, Fungal 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : K23 AI138851
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI118511
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI125003
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Open Forum Infect Dis. 2018 May 24;5(8):ofy122
pubmed: 30094292
Diagn Microbiol Infect Dis. 2016 Mar;84(3):268-73
pubmed: 26711635
Open Forum Infect Dis. 2015 Apr 02;2(2):ofv046
pubmed: 26213690
Trop Med Int Health. 2007 Aug;12(8):929-35
pubmed: 17697087
Clin Infect Dis. 2010 Aug 15;51(4):448-55
pubmed: 20597693
PLoS One. 2012;7(12):e51291
pubmed: 23251485
Clin Infect Dis. 2010 Feb 1;50(3):291-322
pubmed: 20047480
Clin Infect Dis. 2000 Jan;30(1):47-54
pubmed: 10619732
Lancet Infect Dis. 2017 Aug;17(8):873-881
pubmed: 28483415
Clin Infect Dis. 2019 May 30;68(12):2094-2098
pubmed: 30256903
Emerg Infect Dis. 2014 Jan;20(1):45-53
pubmed: 24378231
J Infect Dis. 2014 Jan 1;209(1):74-82
pubmed: 23945372
PLoS One. 2017 Feb 6;12(2):e0171675
pubmed: 28166254
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S152-S159
pubmed: 29514236
Front Microbiol. 2018 Mar 13;9:409
pubmed: 29593675
Clin Infect Dis. 2014 Dec 1;59(11):1607-14
pubmed: 25057102
Clin Infect Dis. 2014 Mar;58(5):736-45
pubmed: 24319084
PLoS One. 2018 Jan 5;13(1):e0190652
pubmed: 29304090
Med Mycol J. 2016;57(3):E41-6
pubmed: 27581774
J Acquir Immune Defic Syndr. 2018 Aug 15;78(5):574-578
pubmed: 29771787
J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):231-238
pubmed: 29509588
Clin Infect Dis. 2008 Jun 1;46(11):1694-701
pubmed: 18433339
Med Mycol. 2016 May;54(4):361-9
pubmed: 26768372
Clin Infect Dis. 2015 Aug 1;61(3):464-7
pubmed: 25838287
Lancet. 2015 May 30;385(9983):2173-82
pubmed: 25765698
J Fungi (Basel). 2017 Dec 02;3(4):
pubmed: 29371581
Clin Infect Dis. 2018 Feb 10;66(5):686-692
pubmed: 29028998
Clin Infect Dis. 2017 Nov 29;65(12):2126-2129
pubmed: 29020172
J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e37-e42
pubmed: 26926942
J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):e85-91
pubmed: 22410867

Auteurs

Radha Rajasingham (R)

Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA radha@umn.edu.

Rachel M Wake (RM)

Centre for Healthcare-Associated Infections, Antimicrobial Resistance and Mycoses, National Institute for Communicable Diseases, Johanneseburg, South Africa.
Institute for Infection and Immunity, St George's University of London, London, United Kingdom.

Tafese Beyene (T)

Asella Teaching Hospital, College of Health Sciences, Arsi University, Asella, Ethiopia.

Andrew Katende (A)

Ifakara Health Institute, Ifakara, United Republic of Tanzania.

Emilio Letang (E)

Ifakara Health Institute, Ifakara, United Republic of Tanzania.
Swiss Tropical and Public Health Institute, Basel, Switzerland.
University of Basel, Basel, Switzerland.
ISGlobal, Hospital Clínic-Universitat de Barcelona, Barcelona, Spain.
Service of Infectious Diseases, Hospital del Mar Research Institute (IMIM), Hospital del Mar, Barcelona, Spain.

David R Boulware (DR)

Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH